Effect of Oral Semaglutide on Small Dense LDL Cholesterol and LDL Triglycerides: An Observational Study with Retrospective Analysis

DOI

Bibliographic Information

Other Title
  • 経口セマグルチドのsmall dense LDL-コレステロール，LDL-トリグリセリドに及ぼす影響，後ろ向き解析による観察研究

Search this article

Description

<p>Objective Small dense (sd) LDL and LDL triglycerides (TG) are potent risk markers of atherosclerotic cardiovascular disease (ASCVD). GLP-1 receptor agonists (RAs) have been reported to reduce the incidence of ASCVD; therefore, we investigated the effect of oral semaglutide on LDL subfractions. Methods In total, 107 patients treated with oral semaglutide were analyzed. Among them, 87 patients were treated with DPP-4 inhibitors prior to the administration of oral semaglutide, while 20 patients were treated with other medications without DPP-4 inhibitors. The numbers of patients taking semaglutide at doses of 3, 7, and 14 mg were 28, 71, and 8, respectively. The sdLDL-C and LDL-TG levels were measured using a direct quantification method. Results. Most patients were relatively young and obese, with an age of 50±13 years and a BMI of 29±6 kg/m2. The administration of semaglutide decreased HbA1c from 7.9 to 7.5 % and body weight from 76.4 to 74.9 kg. sdLDL-C decreased from 32.4 to 28.6 mg/dL and LDL-TG from 15.6 to 14.7 mg/dL. The LDL-C, TG, and HbA1c levels also decreased. The semaglutide dosage and administration method did not affect lipid changes (Δ). ΔsdLDL-C was positively correlated with ΔLDL-C, ΔTG, and ΔHbA1c, whereas ΔLDL-TG was only correlated with ΔHbA1c. Conclusions Oral semaglutide lowered overall LDL and its subfractions, which may contribute to the suppression of ASCVD.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top